Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Cardio Diagnostics Holdings, Inc.

Get SEC filing alerts via email and in your feed for Cardio Diagnostics Holdings, Inc.

CDIO CDIOW

Cardio Diagnostics Holdings, Inc.

About Cardio Diagnostics Holdings, Inc.

Cardio Diagnostics Holdings, Inc. develops AI-driven epigenetic and genetic blood tests for cardiovascular disease risk assessment and early detection. Its flagship products, Epi+Gen CHD and PrecisionCHD, provide personalized insights to clinicians, payors, and health systems. The company aims to shift cardiovascular care from reactive to proactive, leveraging proprietary technology, strategic partnerships, and a broad market opportunity to improve prevention, diagnosis, and management of heart disease.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Cardio Diagnostics Holdings, Inc.

1
1
Cardio Diagnostics Holdings, Inc. Cardio Diagnostics Reports Q1 2026 Revenue Growth to $2,680, Net Loss Increases to $1.79M

Via official filing (AI summary) | 19 days ago | 0 comments

2
1
Cardio Diagnostics Holdings, Inc. Cardio Diagnostics Holdings Reports Fiscal Year 2025 Results with Revenue Decline and Improved Net Loss

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Cardio Diagnostics Holdings, Inc. Cardio Diagnostics Reports 57% Revenue Decline and Increased Net Losses in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Cardio Diagnostics Holdings, Inc. Cardio Diagnostics Reports Revenue Decline and Increased Net Loss for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Cardio Diagnostics Holdings, Inc. Cardio Diagnostics Reports Mixed Q3 Results, Revenue Growth and Improved Losses Amid Ongoing Liquidity Challenges

Via official filing (AI summary) | over 1 year ago | 0 comments